Cardiometabolic Screening for Breast Cancer Survivors
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What data supports the effectiveness of the treatment for assessing 10-year cardiovascular risk in breast cancer survivors?
Is cardiometabolic screening safe for breast cancer survivors?
The studies reviewed do not provide specific safety data for cardiometabolic screening in breast cancer survivors, but they highlight the importance of monitoring cardiometabolic risk factors like obesity, hypertension (high blood pressure), and diabetes, which are common in this group. These factors are associated with increased health risks, suggesting that screening could be beneficial for managing overall health.16789
How does the Cardiometabolic Screening and Enrollment treatment differ from other treatments for breast cancer survivors?
The Cardiometabolic Screening and Enrollment treatment is unique because it focuses on identifying and managing cardiometabolic risk factors, such as high blood pressure, diabetes, and cholesterol issues, in breast cancer survivors, which are not typically addressed by standard cancer treatments. This approach aims to improve long-term health and quality of life by preventing cardiovascular disease, a leading cause of death in these patients.16101112
What is the purpose of this trial?
This research study is being done to implement a screening program for prediabetes, diabetes, dyslipidemia and/or hyperlipidemia, and higher risk of cardiovascular disease in breast cancer survivors. This program will also help to direct individuals with risk factors to community and institutional resources for management.
Research Team
Jennifer Sheng, M.D.
Principal Investigator
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Eligibility Criteria
This clinical trial is for early-stage breast cancer survivors who have finished their local or systemic therapy at least 3 months ago. Participants must be receiving care through specific Johns Hopkins Medical Institute locations and be able to read and speak English. Those with metastatic breast cancer cannot join.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Cardiometabolic Screening Program
Implementation of a screening program for prediabetes, diabetes, dyslipidemia, and cardiovascular disease risk factors in breast cancer survivors
Follow-up
Participants are monitored for changes in HbA1c, LDL, weight, and patient-reported outcomes at 6 and 12 months
Referral and Management
Participants with identified risk factors are referred to community and institutional resources for management
Treatment Details
Interventions
- Assess 10 year risk of cardiovascular event
- Baseline
- Follow-Up
- Interpret BMI
- Interpret HbA1c
- Interpret lipid panel and assess other risk factors
- Prescreening
- Recommendations
- Screening and Enrollment
Find a Clinic Near You
Who Is Running the Clinical Trial?
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Lead Sponsor
Private Philanthropic Funds
Collaborator